Results 221 to 230 of about 19,007,438 (352)

Influence of OSCAR-IB criteria on test-retest reliability of Spectralis SD-OCT retinal thickness measurements in people with Multiple Sclerosis. [PDF]

Mult Scler
Bacchetti A, McCormack B, Lin TY, Filippatou AG, Gakis G, Pellegrini N, Kinder E, Gulati A, Lievers E, Otero-Duran G, Newsome SD, Murphy O, Nourbakhsh B, Fitzgerald KC, Sotirchos ES, Calabresi PA, Saidha S.   +16 more
europepmc   +1 more source

Pace 9/11 Oral History Project [PDF]

, 2011
Iacullo-Bird (Principal Investigator), Maria T., Sowchek (Co-Principal Investigator), Ellen, Thomas (Co-Principal Investigator), Jennifer   +2 more
core   +1 more source

Combining antibody conjugates with cytotoxic and immune‐stimulating payloads maximizes anti‐cancer activity

Molecular Oncology, EarlyView.
Methods to improve antibody–drug conjugate (ADC) treatment durability in cancer therapy are needed. We utilized ADCs and immune‐stimulating antibody conjugates (ISACs), which are made from two non‐competitive antibodies, to enhance the entry of toxic payloads into cancer cells and deliver immunostimulatory agents into immune cells.
Tiexin Wang, Dong Jun Koo, Peter M. Tessier, Greg M. Thurber   +3 more
wiley   +1 more source

Cytomegalovirus (CMV)-Specific Cell-Mediated Immunity for Prediction of Postprophylaxis CMV Disease in a Phase 3 Trial of Letermovir Versus Valganciclovir Prophylaxis in Donor CMV-Seropositive/Recipient CMV-Seronegative Kidney Transplant Recipients. [PDF]

Clin Infect Dis
Limaye AP, Crespo M, Kamar N, Humar A, Carroll RP, Pereira MR, Broyde N, Wang W, Haber B.   +8 more
europepmc   +1 more source

Investigator Characteristics and Respondent Behavior in Online Surveys

Journal of Experimental Political Science, 2018
A. White, Anton Strezhnev, Christopher Lucas, Dominika Kruszewska, Connor Huff   +4 more
semanticscholar   +1 more source

Dammarenediol II enhances etoposide‐induced apoptosis by targeting O‐GlcNAc transferase and Akt/GSK3β/mTOR signaling in liver cancer

Molecular Oncology, EarlyView.
Etoposide induces DNA damage, activating p53‐dependent apoptosis via caspase‐3/7, which cleaves PARP1. Dammarenediol II enhances this apoptotic pathway by suppressing O‐GlcNAc transferase activity, further decreasing O‐GlcNAcylation. The reduction in O‐GlcNAc levels boosts p53‐driven apoptosis and influences the Akt/GSK3β/mTOR signaling pathway ...
Jaehoon Lee, Byung‐Cheol Han, Gi‐Bang Koo, Jihye Park, Mijin Kwon, Young Bin Park, Jae‐Mun Choi, Seung‐Ho Lee, Sangho Roh   +8 more
wiley   +1 more source

"Doing the Best I Can": Qualitative Outcomes and Participant Feedback From a Combined Communication and Counselling Treatment for Primary Progressive Aphasia. [PDF]

Int J Lang Commun Disord
Schaffer Mendez K, Evans WS, Dutcher CD, Philburn C, Wauters LD, Young MM, Henry ML.   +6 more
europepmc   +1 more source

Tumor mutational burden as a determinant of metastatic dissemination patterns

Molecular Oncology, EarlyView.
This study performed a comprehensive analysis of genomic data to elucidate whether metastasis in certain organs share genetic characteristics regardless of cancer type. No robust mutational patterns were identified across different metastatic locations and cancer types.
Eduardo Candeal, Andrea Moreno‐Manuel, Miguel Salvadó‐Pertierra, Cristina Santos‐Vivas, Rebeca Sanz‐Pamplona   +4 more
wiley   +1 more source

MR GENTLE-multicentre randomised controlled trial of ghrelin in anterior circulation ischaemic stroke treated with endovascular thrombectomy: a phase 2 trial. [PDF]

Trials
Omes QPM, van der Veen D, Kersten CJBA, Arntz RM, Filius PMG, van den Wijngaard IR, van der Worp HB, Hofmeijer J.   +7 more
europepmc   +1 more source

TRAIL‐PEG‐Apt‐PLGA nanosystem as an aptamer‐targeted drug delivery system potential for triple‐negative breast cancer therapy using in vivo mouse model

Molecular Oncology, EarlyView.
Aptamers are used both therapeutically and as targeting agents in cancer treatment. We developed an aptamer‐targeted PLGA–TRAIL nanosystem that exhibited superior therapeutic efficacy in NOD/SCID breast cancer models. This nanosystem represents a novel biotechnological drug candidate for suppressing resistance development in breast cancer.
Gulen Melike Demirbolat, Aslihan Kucuk, Omer Erdogan, Samed Ozer, Bensu Kozan, Tugba Cuceli, Erkan Gumus, Evrim Cevik, Ozge Cevik   +8 more
wiley   +1 more source